title: Understanding anti-leukemia responses to donor lymphocyte infusion.
abstract: Donor lymphocyte infusion (DLI) is an established and potentially curative immune therapy for relapsed leukemia after hematopoietic stem cell transplant (HSCT). Herein, we describe the utility of DLI as a tractable model system to glean fresh insights into understanding and predicting effective anti-leukemia immunity.
authors.affiliation: Department of Medical Oncology; Dana-Farber Cancer Institute; Boston, MA USA ; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.
authors.forename: Pavan
authors.initials: P
authors.lastname: Bachireddy
authors.affiliation: Department of Medical Oncology; Dana-Farber Cancer Institute; Boston, MA USA ; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Wu
keywords: CML; T cell exhaustion; donor lymphocyte infusion; stem cell transplantation; tumor-infiltrating lymphocytes